Razi Institute Chief Underlines High Efficiency of Iran-Made Razi Cov Pars Vaccine
TEHRAN (FNA)- The Iran-made Razi Cov Pars vaccine, produced by Razi Vaccine and Serum Research Institute, is highly effective against COVID-19 virus more than certain foreign types, the institute chief said.
Iran's Razi Cov Pars COVID-19 vaccine is proving to be more effective than some imported types and there has been demand for it from a number of countries, Head of Iran's Razi Serum and Vaccine Research Institute Ali Eshaqi said.
He added that the superiority of Razi Cov Pars over China’s Sinopharm was proven in the third phase of the clinical trial.
“In this phase, in the group that received the Sinopharm vaccine, two weeks after the second injection, the number of patients with Covid-19 was more than twice the number in Razi Cov Pars group. Also, during this period, we did not have any hospitalization among the recipients of Razi, but in the Sinopharm vaccine group, five cases were hospitalized,” he added.
Eshaqi said the third stage of the human trial of Razi Cov Pars vaccine has been completed, adding that the emergency use for this vaccine was authorized in September and that so far five million doses of this vaccine have been delivered to the health ministry.
He noted that Razi can be a suitable vaccine for children, adding that the clinical test protocol for children has been prepared and the relevant committee will issue a permit next week.
Saying that a number of countries have asked to buy the Iranian vaccine, Eshaqi said, “Our priority is to meet domestic needs, but given the good level of imports and the appropriate trend of domestic vaccine production, we expect an export license to be given to Razi Group.”
Razi Cov Pars is a recombinant protein subunit vaccine containing the COVID-19 spike protein. It reportedly tutors the immune system against the virus by producing antibodies.
The vaccine includes three doses. The first two doses are said to be injectable, whilst the third dose is intranasal.